NCT07826507尚未招募1 期
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Phase 1b/2a Clinical Trial to Evaluate The Safety, Tolerability, Pharmacokinetics, and Efficacy of a Transtympanic Injection of Paliroden (CIL001) for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- Cilcare SAS
- 入组人数
- 60
- 主要终点
- Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs) from baseline to 6 months (168 days). Safety data, including all observed AEs with a particular focus on ear and auditory symptomatology.
研究概览
简要总结
The goal of this clinical trial is to investigate if paliroden (CIL001) is safe and can help treat cochlear synaptopathy in adult participants 18-75 years of age with normal hearing thresholds and normal cognition who exhibit chronic, constant tinnitus in both ears and have difficulty understanding speech in noisy environments. The main questions it aims to answer are:
- Is the study drug safe and tolerable over 6 months after injection into the middle ear?
- How much of the study drug is in the bloodstream at different time points after injection?
- How effective is a single dose of the study drug at treating cochlear synaptopathy in participants with chronic, constant tinnitus, as measured by hearing and listening tests?
Injection of the study drug will be compared to injection of a placebo (a substance with no study drug in it) to see if there is a difference.
Participants will be screened for eligibility and potentially receive a one-time injection into the middle ear of paliroden or placebo. The study lasts approximately 6 to 7 months if completing the whole study. Based on the visit windows, this could be between 190 and 218 days including a maximum of 42 days for Screening & Run-in and 175 days post-treatment.
Participants will:
- Visit the clinic for checkups and tests multiple times over the course of the study
- Complete a large battery of hearing and listening tests, answer questionnaires about their experiences, and provide blood samples for various tests
- Receive an injection of either the study drug or placebo (a substance that has no active drug in it), if eligible
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Native speaker of English
- •Able and willing to give consent for the study
- •Age 18-75 years (inclusive) at the time of signing the informed consent
- •Report binaural, chronic, constant, subjective tinnitus for at least 6 months
- •Hearing thresholds within normal limits (≤ 20 dB HL at 0.25 to 8 kHz, plus 3 and 6 kHz)
- •Speech-in-noise deficit (at least 3 dB SNR loss in comparison to normative value of the AE-Matrix test) in both ears
- •No concurrent tinnitus treatment
- •Be considered as reliable and capable of adhering to the protocol, according to the judgment of the investigator
- •Signed informed consent as described in § 11.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
排除标准
- •Montreal Cognitive Assessment (MoCA) score < 26
- •History of somatic/objective tinnitus as defined by AAO-HNS guidelines (e.g., pulsatile/whooshing sounds pulsating in synchrony with heartbeat, or caused by temporo-mandibular joint dysfunction)
- •Known otologic pathology (e.g., otosclerosis, history of autoimmune hearing loss, radiation-induced hearing loss, fluctuating hearing, endolymphatic hydrops, Ménière's disease, vestibular schwannoma, history of sudden sensorineural hearing loss, Neurofibromatosis Type 2)
- •History of otologic surgery (apart from tympanostomy tube insertion if more than one year prior to inclusion visit)
- •Untreated hypothyroidism
- •Use of prohibited concomitant therapies as described in § 6.10
- •Current use or history of platinum-based chemotherapy
- •Concurrent malignancies that require treatment
- •Abnormal otoscopy as defined by less than 90% of the tympanic membrane visible (e.g., occluding cerumen, ear drum perforation)
- •Current middle ear pathology (e.g., otitis media, tympanic membrane perforation)
- •Abnormal tympanogram (other than type A)
- •Conductive hearing loss (> 10 dB difference between air- and bone-conduction hearing thresholds)
- •Asymmetric hearing thresholds (more than 15 dB difference between left and right ear) at 0.25 to 8 kHz, plus 3 and 6 kHz
- •Lactation, known pregnancy, positive pregnancy test at either Screening (urine) or Baseline (serum) for Women of Childbearing Potential (WOCBP), or plan to become pregnant during the study
- •Liver Enzyme Lab Outcomes within the previous 2 months (or assessed at Baseline if not available at Screening ), see § 12.1.1:
- •Bilirubin > upper limit normal (ULN)
- •Liver transaminases (Aspartate Aminotransferase [AST] and Alanine Aminotransferase [ALT]) > 2 times ULN
- •Gamma-glutamyltransferase (GGT) > 2 times ULN
- •Clinically significant electrocardiogram (ECG) abnormalities:
- •a. Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 450 ms)
- •History of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- •Concurrent participation in another clinical study or participation in another clinical study within 30 days or five half-lives of the experimental drug (whichever is longer) prior to screening visit (V0)
- •Diagnosed anxiety disorders, psychosis, depression, schizophrenia, attempted suicide, or other significant psychiatric conditions that could impact their ability to cooperate and comply with the study protocol
- •Major surgery (at the discretion of the Principal Investigator or medically qualified designee) within eight weeks before screening or scheduled/planned surgery within the time frame of the study
研究组 & 干预措施
paliroden (CIL001)
Experimental
Those receiving a one-time unilateral transtympanic injection of 0.4mL of paliroden (CIL001)
干预措施: paliroden (CIL001) (Drug)
Placebo
Placebo Comparator
Those receiving a one-time unilateral transtympanic injection of 0.4mL of non-matching placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs) from baseline to 6 months (168 days). Safety data, including all observed AEs with a particular focus on ear and auditory symptomatology.
时间窗: From baseline to 6 months (168 days) after injection
次要结局
- Determine the concentration in plasma of paliroden with Area under the plasma concentration versus time curve (AUC)(From the day of injection to 28 days)
- Determine the concentration in plasma of paliroden with Peak Plasma Concentration (Cmax)(From the day of injection to 28 days)
- Determine the time to maximum plasma concentration (Tmax).(From the day of injection to 28 days)
- Change from baseline in auditory function using speech-in-noise intelligibility as measured by the English (US) Matrix Test (AE-Matrix) and Time Compressed Words.(From baseline to day 28, day 56, day 84, and day 168)
研究者
相似试验
尚未招募
3 期
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NECAdvanced Extrapulmonary Neuroendocrine CarcinomaNCT07720193Nanjing Leads Biolabs Co.,Ltd280
尚未招募
2 期
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseMultiple Myeloma (MM)NCT07811986Institute of Hematology & Blood Diseases Hospital, China20
尚未招募
3 期
A Study to evaluated the Effectiveness of Korglutide in Weight Management in Non-Diabetic Individuals with Elevated Body Fat and Normal to Overweight BMI.CTRI/2025/08/092392Biosite Research Private Limited198
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back PainNCT07641504Eli Lilly and Company150
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainOsteoarthritis, KneeNCT07641517Eli Lilly and Company150